Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy
Andrew D. Wells, … , Jeffrey A. Bluestone, Laurence A. Turka
Andrew D. Wells, … , Jeffrey A. Bluestone, Laurence A. Turka
Published September 15, 2001
Citation Information: J Clin Invest. 2001;108(6):895-904. https://doi.org/10.1172/JCI13220.
View: Text | PDF
Article Article has an altmetric score of 7

Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy

  • Text
  • PDF
Abstract

Primary T cell proliferative responses to TCR ligation plus CD28 costimulation are surprisingly heterogeneous. Many cells that enter G1 fail to progress further through the cell cycle, and some of these cells subsequently fail to divide upon restimulation, even in the presence of IL-2. Such IL-2–refractory anergy is distinct from the IL-2–reversible anergy induced by TCR occupancy in the absence of CD28 costimulation. Here, we focus on the contributions of cell cycle progression and costimulatory (CD28/CTLA-4) signals in the regulation of anergy. We show that CD28 costimulation is not sufficient for anergy avoidance and that activated T cells must progress through the cell cycle in order to escape anergy. Induction of this “division-arrest” form of anergy requires CTLA-4 signaling during the primary response. Also, cell division per se is not sufficient for anergy avoidance: the few T cells that undergo multiple rounds of cell division during overt CD28 costimulatory blockade do not escape the ultimate induction of clonal anergy. Anergy avoidance by primary T cells is thus a multistep process: in order to participate in a productive immune response, an individual T cell activated through its antigen receptor must receive CD28 costimulation and progress through the cell cycle. Anergy may be induced either through a combination of CTLA-4 signaling and the failure of cell cycle progression, or through a proliferation-independent mechanism in which TCR ligation occurs in the absence of CD28.

Authors

Andrew D. Wells, Matthew C. Walsh, Jeffrey A. Bluestone, Laurence A. Turka

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Regulation of secondary T cell proliferation by CTLA-4–mediated signal t...
Regulation of secondary T cell proliferation by CTLA-4–mediated signal transduction and cell division during the primary response. (a–h) CFSE-labeled splenocytes were stimulated with anti-CD3 in the presence of hamster IgG (first and second sets of columns in h), or either anti–CTLA-4 antibody (10 μg/ml; n = 2) or anti–CTLA-4 Fab (20 μg/ml; n = 2; a–g). Experiments using whole and Fab fragments of anti–CTLA-4 antibody gave similar results and are shown combined as n = 4 experiments (h, third and fourth sets of columns). Cultures were rested for 48 hours, and Thy1.2+ cells that had divided twice (b, d, and f; shaded bars in h) or had remained undivided (c, e, and g; open bars in h) following primary stimulation were purified by FACS. The sorted T cells were cultured with irradiated APCs and restimulated with anti-CD3 in the presence or absence of exogenous IL-2, and proliferation was assessed 4 days later by flow cytometry. One representative experiment is depicted graphically in a–g. The mean secondary mitotic events of separate experiments (n = 4, as described above) are plotted in h. The data from the control cultures (first and second sets of columns in h) are the same as depicted in Figure 1. Statistically significant differences were assessed by paired t test and are denoted by brackets: *P < 0.05; **P < 0.01; ***P < 0.001. (i) Lymph node and spleen cells were cultured with anti-CD3 in combination with anti-CD28 (first lane) or anti–CTLA-4 (second lane). The cultures were then rested for 24 hours (first panel), and a portion of the T cells were restimulated with anti-CD3–coated beads (second panel) for 48 hours. In a separate experiment, lymph node and spleen cells were stimulated as above, rested (third panel), and stimulated with IL-2 (50 U/ml; fourth panel) for 48 hours. Live cells were isolated over Ficoll, and lysates were subjected to immunoblot analysis using antibodies against p27kip1 or actin (fifth panel). The results shown are representative of two independent experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 4 patents
Highlighted by 1 platforms
85 readers on Mendeley
See more details